Adoption of the profit and loss statement and the balance sheet
The Annual General Meeting adopted the profit and loss statement and the balance sheet for the Company for the 2021 financial year.

The company’s profits or losses according to the adopted balance sheet
The Annual General Meeting resolved that the Company’s results shall be carried forward in new account and that no dividend shall be paid for the financial year 2021.

The members of the board of directors’ and the CEO’s discharge from liability
The Annual General Meeting resolved that the Board of Directors and the CEO shall be discharged from liability for the financial year 2021.

Determination of the fees payable to the members of the board of directors and the auditor
In accordance with the Nomination committee’s proposal, the Annual General Meeting resolved that the fees to the Board of Directors, until the end of the next annual general meeting, shall amount to SEK 155,000 to be distributed between the members of the Board of Directors who are not employed by the Company or related party to an employee of the Company.

The Annual General Meeting also resolved that fees to the auditor are paid in accordance with approved invoices and customary billing standards.

Election of members of the board of directors and auditor
In accordance with the Nomination committee’s proposal, the Annual General Meeting resolved to re-elect Leif Gustafsson, Anders Hult, Michael Malkoch, Mats Wallnér and Eva Malmström Jonsson as members of the Board. The Annual General Meeting also resolved to re-elect Eva Malmström Jonsson as Chairperson of the Board.

In accordance with the Nomination committee’s proposal, the Annual General Meeting resolved to re-elect as auditor registered the auditing company PwC, represented by Niclas Bergenmo as the principal auditor.

Nomination Committee
In accordance with the Nomination committee’s proposal, the Annual General Meeting resolved that the Nomination Committee prior to the 2023 Annual General Meeting shall be appointed no later than six months before the 2023 Annual General Meeting, where representatives of the three largest shareholders are primarily offered a seat. The representative from one of the company's largest owners shall be the chairperson of the nomination committee, unless otherwise determined within the nomination committee. The Nomination Committee's work shall follow the Swedish Code of Corporate Governance and the rules of procedure adopted by the AGM.

Authorization for the Board of Directors to resolve on new share issues
In accordance with the Board of Directors’ proposal, the Annual General Meeting resolved to authorize the Board of Directors to, on one or more occasions, before the next Annual General Meeting, decide on a new issue of ordinary shares with or without deviation from the shareholders' preferential rights, within the scope of the current Articles of Association. Through such a new share issue, it shall be possible to increase the share capital by issuing shares on market terms, however, the number of newly issued shares shall in total not exceed 5,000,000, corresponding to an increase in the company's share capital of a maximum of SEK 500,000. The authorization shall include the right to decide on an issue against cash payment, payment with non-cash assets or payment by set-off.

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.